Biotech Top Losers: VIVUS (NASDAQ:VVUS), Arrowhead Research Corp (NASDAQ:ARWR), Advaxis (NASDAQ:ADXS), Trevena Inc (NASDAQ:TRVN)

Vivus Inc. (NASDAQ:VVUS) Pharmaceuticals is having an absolutely awful day, with the stock down more than 13% after the company reported its Q4 results. VIVUS, Inc. (NASDAQ:VVUS) stock opened at $5.77 in last session, and closed at $5.86, while the day range of VVUS stock is $5.77 – $6.24. The stock showed a negative weekly performance of -18.61%.

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that on February 24, 2014 it closed the previously announced underwritten offering of 6,325,000 shares of common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 825,000 additional shares. Arrowhead Research Corp (NASDAQ:ARWR) stock opened at $22.47, in last session and closed at $21.23, by losing -5.22%. The 52 week range of ARWR is $1.65 – $23.14. Company’s market capitalization is $944.78million.

Georgia Regents University Cancer Center has entered into a master clinical trial agreement with Advaxis Inc. (NASDAQ:ADXS), a biotechnology company specializing in cancer immunotherapies. Under the terms of the agreement, the Cancer Center will conduct four clinical trials under the supervision of Cancer Center Director Dr. Samir N. Khleif. Advaxis, Inc. (NASDAQ:ADXS) stock decreased -6.51% and finished the last session at $4.74. The EPS of the stock remained -4.31. Company’s market capitalization is $65.75million.

Equities researchers at Barclays initiated coverage on shares of Trevena Inc (NASDAQ:TRVN) in a research report issued on Wednesday, Analyst RN reports. The firm set an “overweight” rating and a $14.00 price target on the stock. Trevena Inc (NASDAQ:TRVN) stock opened the session at $8.00, and closed the session at $7.77. The 52 week range of the TRVN stock remained $6.35 – $8.98 and the day range was $7.57 – $8.00.